熱門資訊> 正文
富国银行称,维罗纳开始超重,称慢性阻塞性肺病药物被低估
2024-10-04 00:21
- Wells Fargo initiated coverage of Verona Pharma (NASDAQ:VRNA) with an overweight rating, asserting that the company's recently launched drug for COPD, Ohtuvayre, is being undervalued by the Street.
- The investment bank said the market has been pricing in peak sales of around $750M for the drug, but early feedback from prescribers suggests the drug could generate roughly $2B, “with $3B+ being a real possibility.”
- Wells Fargo set its price target for the stock at $50.
More on Verona Pharma
- Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care
- Verona Pharma: A Post FDA Approval Analysis
- Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript
- Verona Pharma GAAP EPS of -$0.11 beats by $0.10
- Verona Pharma Q2 2024 Earnings Preview
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。